CC
Therapeutic Areas
Halozyme Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Darzalex Faspro® (with Janssen) | Multiple Myeloma | Approved |
| Phesgo® (with Roche) | HER2+ Breast Cancer | Approved |
| Rituxan Hycela® (with Roche) | Non-Hodgkin's Lymphoma, CLL | Approved |
| Tecentriq® SC (with Roche) | Various Cancers | Phase III |
| HyQvia® (with Takeda) | Primary Immunodeficiencies | Approved |
| Dulaglutide (Trulicity) (with Lilly) | Type 2 Diabetes | Approved |
| Undisclosed SC Formulation (with Bristol Myers Squibb) | Undisclosed | Phase I/II |
| Undisclosed SC Formulation (with Pfizer) | Undisclosed | Preclinical/Phase I |
Leadership Team at Halozyme Therapeutics
HT
Helen Torley
President and Chief Executive Officer
MS
Mark Snyder
Chief Legal Officer
CC
Chase Coffman
President of Hypercon™